Avitar, Inc. (AVTI)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Avitar, Inc. (AVTI) with AI Score 45/100 (Weak). Avitar, Inc. operates as a holding company, focusing on the design, development, manufacture, and marketing of diagnostic test products and proprietary hydrophilic polyurethane foam disposables. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026Avitar, Inc. (AVTI) Healthcare & Pipeline Overview
Avitar, Inc. is a holding company specializing in diagnostic testing and medical disposables, offering onsite drug detection systems and hydrophilic polyurethane foam products. Targeting medical, diagnostic, dental, and consumer sectors, the company utilizes direct sales and strategic partnerships for distribution within the United States.
Investment Thesis
Avitar, Inc. presents a speculative investment opportunity within the medical devices and diagnostics sector. With a negative P/E ratio and a negative profit margin of -72.7%, the company's financial performance raises concerns about its profitability and sustainability. The company's gross margin stands at 26.9%. Growth catalysts include potential expansion of its ORALscreen product line into new markets and increased adoption of its wound care products. However, the company's small market capitalization and OTC listing introduce significant risks related to liquidity and regulatory compliance. The company's high beta of -51.52 suggests high volatility relative to the market. Investors should carefully consider these factors and conduct thorough due diligence before investing.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- Negative P/E ratio suggests the company is currently not profitable.
- Profit margin of -72.7% highlights significant challenges in achieving profitability.
- Gross margin of 26.9% indicates the company's ability to generate revenue after covering the cost of goods sold.
- Beta of -51.52 suggests the stock price moves inversely to the market.
Competitors & Peers
Strengths
- Proprietary technology in hydrophilic polyurethane foam.
- Established presence in the drug detection market with ORALscreen.
- Specialized wound care products addressing specific medical needs.
- Direct sales force and strategic partnerships for distribution.
Weaknesses
- Negative profitability and low market capitalization.
- Limited financial resources for research and development.
- Dependence on a small number of products and markets.
- OTC listing introduces liquidity and regulatory risks.
Catalysts
- Upcoming: Potential FDA approval for new diagnostic tests, expanding the product portfolio.
- Ongoing: Expansion of the ORALscreen product line into new geographic markets.
- Ongoing: Strategic partnerships with medical facilities to increase adoption of wound care products.
Risks
- Potential: Competition from larger companies in the medical devices and diagnostics industry.
- Potential: Regulatory changes affecting drug testing and medical device approvals.
- Ongoing: Negative profitability and low market capitalization.
- Ongoing: OTC listing introduces liquidity and regulatory risks.
- Potential: Product liability claims and recalls.
Growth Opportunities
- Expansion of ORALscreen product line: Avitar has the opportunity to expand the market reach of its ORALscreen drug detection systems. The market for drug testing is growing, driven by increasing concerns about workplace safety and substance abuse. By targeting new industries and geographies, Avitar can increase sales and market share. The global drug testing market is projected to reach $8.7 billion by 2027, offering a substantial growth opportunity for Avitar.
- Increased adoption of wound care products: Avitar's Hydrasorb and Illizarov dressings address specific needs in wound care management. The market for advanced wound care products is expanding due to the rising incidence of chronic wounds and surgical procedures. By focusing on product innovation and strategic partnerships with medical facilities, Avitar can drive adoption of its wound care solutions. The advanced wound care market is expected to reach $22 billion by 2028.
- Development of new diagnostic tests: Avitar can leverage its expertise in diagnostic test development to create new products for detecting various medical conditions. The demand for rapid and accurate diagnostic tests is increasing, driven by the need for early disease detection and personalized medicine. By investing in research and development, Avitar can expand its product portfolio and address unmet needs in the diagnostics market. The global diagnostics market is projected to reach $125 billion by 2025.
- Strategic partnerships and acquisitions: Avitar can pursue strategic partnerships and acquisitions to expand its product offerings and market reach. Collaborating with other companies in the medical devices and diagnostics industry can provide access to new technologies, distribution channels, and customer segments. By carefully selecting partners and acquisition targets, Avitar can accelerate its growth and enhance its competitive position. The medical device industry is witnessing increasing consolidation, creating opportunities for strategic alliances.
- Geographic expansion: Avitar primarily operates in the United States and Canada. Expanding into new geographic markets, such as Europe and Asia, can significantly increase its revenue potential. These regions have growing healthcare expenditures and increasing demand for advanced medical devices and diagnostics. By establishing a presence in these markets through partnerships or direct investment, Avitar can tap into new sources of growth. The emerging markets in Asia are expected to drive significant growth in the healthcare industry.
Opportunities
- Expansion of ORALscreen product line into new markets.
- Increased adoption of wound care products in hospitals and clinics.
- Development of new diagnostic tests for various medical conditions.
- Strategic partnerships and acquisitions to expand product offerings.
Threats
- Competition from larger companies in the medical devices and diagnostics industry.
- Regulatory changes affecting drug testing and medical device approvals.
- Economic downturn impacting healthcare spending.
- Product liability claims and recalls.
Competitive Advantages
- Proprietary hydrophilic polyurethane foam technology.
- Established relationships with strategic partners and distributors.
- Specialized product offerings in niche markets (e.g., Illizarov Dressing).
- Brand recognition for ORALscreen drug detection systems.
About AVTI
Founded in 1986 and based in Canton, Massachusetts, Avitar, Inc. functions as a holding company with a focus on the healthcare and diagnostics industries. The company, through its subsidiaries, designs, develops, manufactures, and markets a range of diagnostic test products and proprietary hydrophilic polyurethane foam disposables. These products cater to medical, diagnostics, dental, and consumer applications within the United States. Avitar's offerings include ORALscreen 4 and ORALscreen DRUGOMETER, oral fluid-based onsite assay systems designed for the detection of drugs of abuse, such as opiates, cocaine, marijuana, and methamphetamines. Additionally, the company provides medical-grade hydrophilic polyurethane foam disposables, including wound dressings like Hydrasorb, and custom foam products such as sinus dressings and devices used by astronauts for ear pressure relief. Avitar also develops specialty wound dressings for the cardiac catheter lab market and the Illizarov Dressing for orthopedic procedures. The company markets its products through a direct sales force, strategic partners, and a network of distributors, targeting employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations.
What They Do
- Designs, develops, manufactures, and markets diagnostic test products.
- Offers oral fluid-based onsite assay systems for detecting drugs of abuse (ORALscreen 4 and ORALscreen DRUGOMETER).
- Provides medical-grade hydrophilic polyurethane foam disposables, including wound dressings (Hydrasorb).
- Develops custom foam products for medical and consumer applications.
- Creates specialty wound dressings for the cardiac catheter lab market.
- Produces the Illizarov Dressing for dressing external bone fixators in orthopedic procedures.
Business Model
- Develops and manufactures diagnostic test products and medical disposables.
- Markets products to employers, diagnostic test distributors, medical supply companies, governmental agencies, schools, and corporations.
- Utilizes a direct sales force and strategic partners for distribution.
- Generates revenue through the sale of diagnostic tests and medical disposables.
Industry Context
Avitar, Inc. operates within the medical devices and diagnostics industry, a sector characterized by technological innovation and stringent regulatory oversight. The industry is driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in diagnostic technologies. Competition is intense, with established players and emerging companies vying for market share. Avitar's focus on onsite drug detection and specialized wound care products positions it within niche segments of this broader market. The company's success depends on its ability to innovate, obtain regulatory approvals, and effectively market its products.
Key Customers
- Employers seeking drug testing solutions for workplace safety.
- Diagnostic test distributors supplying medical facilities and laboratories.
- Medical supply companies providing products to hospitals and clinics.
- Governmental agencies requiring drug testing and medical supplies.
- Schools and corporations implementing drug testing programs.
Financials
Chart & Info
Avitar, Inc. (AVTI) stock price: Price data unavailable
Latest News
No recent news available for AVTI.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for AVTI.
Price Targets
Wall Street price target analysis for AVTI.
MoonshotScore
What does this score mean?
The MoonshotScore rates AVTI's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Cory H. Gelmon
Unknown
Information about Cory H. Gelmon's background is not available in the provided data. Without further information, it is not possible to provide details about his career history, education, or previous roles.
Track Record: Information about Cory H. Gelmon's track record is not available in the provided data. Without further information, it is not possible to provide details about key achievements, strategic decisions, or company milestones under his leadership.
AVTI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Avitar, Inc. may not meet the minimum financial standards or reporting requirements for higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the potential for limited information and regulatory oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Low trading volume and liquidity can lead to price volatility.
- Higher risk of fraud and manipulation compared to listed exchanges.
- Limited regulatory oversight and investor protection.
- Potential delisting or trading suspension due to non-compliance.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Check for any history of fraud or regulatory violations.
- Consult with a financial advisor before investing.
- The company has been in operation since 1986.
- Avitar has a portfolio of diagnostic test products and medical disposables.
- The company markets its products through a direct sales force and strategic partners.
- Avitar has a physical headquarters in Canton, Massachusetts, and an additional office in Calgary, Canada.
- The company's products are used in medical, diagnostic, dental, and consumer applications.
Common Questions About AVTI
What does Avitar, Inc. do?
Avitar, Inc. is a holding company that, through its subsidiaries, focuses on designing, developing, manufacturing, and marketing diagnostic test products and proprietary hydrophilic polyurethane foam disposables. Their primary offerings include ORALscreen drug detection systems and Hydrasorb wound dressings, targeting the medical, diagnostic, dental, and consumer sectors. The company distributes its products through a direct sales force, strategic partners, and a network of distributors, serving employers, medical facilities, governmental agencies, and schools.
What do analysts say about AVTI stock?
AI analysis is currently pending for AVTI. Given the company's OTC listing and limited financial information, analyst coverage is likely sparse. Key valuation metrics such as P/E ratio are currently negative, reflecting the company's lack of profitability. Growth considerations include the potential for expansion in the drug testing and wound care markets, but investors should carefully assess the risks associated with investing in a micro-cap OTC stock.
What are the main risks for AVTI?
Avitar, Inc. faces several risks, including intense competition in the medical devices and diagnostics industry, regulatory hurdles related to drug testing and medical device approvals, and the company's current lack of profitability. As an OTC-listed company, AVTI is subject to liquidity constraints and limited regulatory oversight, increasing the risk of price volatility and potential fraud. Investors should also consider the potential for product liability claims and recalls, which could negatively impact the company's financial performance and reputation.
What are the key factors to evaluate for AVTI?
Avitar, Inc. (AVTI) currently holds an AI score of 45/100, indicating low score. Key strength: Proprietary technology in hydrophilic polyurethane foam.. Primary risk to monitor: Potential: Competition from larger companies in the medical devices and diagnostics industry.. This is not financial advice.
How frequently does AVTI data refresh on this page?
AVTI prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven AVTI's recent stock price performance?
Recent price movement in Avitar, Inc. (AVTI) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary technology in hydrophilic polyurethane foam.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider AVTI overvalued or undervalued right now?
Determining whether Avitar, Inc. (AVTI) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying AVTI?
Before investing in Avitar, Inc. (AVTI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is limited due to the company's OTC listing and disclosure status.
- AI analysis is pending and may provide additional insights.